Colon cancer is one of the most common tumors of the digestive tract. Resistance to ionizing radiation (IR) decreased therapeutic efficiency in these patients’ radiotherapy. XRCC2 is the key protein of DNA homologous recombination repair, and its high expression is associated with enhanced
[...] Read more.
Colon cancer is one of the most common tumors of the digestive tract. Resistance to ionizing radiation (IR) decreased therapeutic efficiency in these patients’ radiotherapy. XRCC2 is the key protein of DNA homologous recombination repair, and its high expression is associated with enhanced resistance to DNA damage induced by IR. Here, we investigated the effect of
XRCC2 silencing on colon tumor cells’ growth and sensitivity to X-radiation
in vitro and
in vivo. Colon tumor cells (T84 cell line) were cultivated
in vitro and tumors originated from the cell line were propagated as xenografts in nude mice. The suppression of
XRCC2 expression was achieved by using vector-based short hairpin RNA (shRNA) in T84 cells. We found that the knockdown of
XRCC2 expression effectively decreased T84 cellular proliferation and colony formation, and led to cell apoptosis and cell cycle arrested in G2/M phase induced by X-radiation
in vitro. In addition, tumor xenograft studies suggested that
XRCC2 silencing inhibited tumorigenicity after radiation treatment
in vivo. Our data suggest that the suppression of
XRCC2 expression rendered colon tumor cells more sensitive to radiation therapy
in vitro and
in vivo, implying
XRCC2 as a promising therapeutic target for the treatment of radioresistant human colon cancer.
Full article